Rallybio in-licenses RLYB331 from Sanofi; Q1 net loss $14.5M, cash $161.4M

Rallybio Corp

Exclusive worldwide license from Sanofi for preclinical anti-MTP-2 antibody RLYB331; upfront $3M, up to $43M development & $150M commercial milestones.
Q1 2022 net loss of $14.5M ($0.48 per share) vs. $13.3M ($0.60) in Q1 2021; R&D spend $7.6M, G&A $6.7M.
Cash, equivalents & marketable securities $161.4M as of March 31, 2022.
Phase 1b proof-of-concept study for RLYB212 (FNAIT) initiated; initial data expected in Q3 2022.
Phase 1 study of RLYB116 (complement inhibitor) ongoing; single-dose data expected in H2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.